Pathogen-microbiome Interaction During Helicobacter Pylori Infection

Condition(s) studied

Investigational drug(s) / intervention(s)

Analysis of gut microbiome and immune signatures: The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.

Study summary

Helicobacter pylori affects the gut microbiome in ways that are only partially understood. In which patients H. pylori causes severe disease and in whom it merely colonizes, possibly even with beneficial effects, is not understood. The investigators are pursuing the hypothesis that changes in the gut microbiome that can be easily measured in stool have such predictive value.

Eligibility

Primary outcome measure(s)

• Helicobacter pylori microbiome and immune signatures — 12-18 Months
  The diversity of the gut microbial species of patients and controls as well as transcriptomic signatures of blood immune cells will be assessed and compared to conclude specisifc signatures that are associated with the disease and carrier status. These signatures will be analyzed to identify specific bacterial and immune biomarkers that can be used as a screening tool for Helicobacter pylori infection.

Trial sites (1)

More University Hospital Freiburg trials in Germany

Other trials for the same condition